The Global Ciclesonide
Market, by Indication (Asthma and Allergic Rhinitis), by Dosage Form
(Aerosol and Nasal Spray), and by Region (North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa) was valued at US$ 565.4 million in 2018,
and is projected to exhibit a CAGR of 1.9% over the forecast period (2018 –
2026).
Inhaled corticosteroids (ICS)
such as ciclesonide are at the cornerstone of treatment in asthma and in
chronic obstructive pulmonary disease (COPD). The majority of the asthma
patients, are treated with a combination of ICS and short- or long- acting
bronchodilators. High efficiency of inhaled corticosteroids in treating asthma
and COPD incidences is supporting adoption of ciclesonide in the future. For
instance, according to the study findings published in the BMJ Journal, in November
2018, use of triple therapy consisting of a long acting muscarinic antagonist
(LAMA), long acting β agonist (LABA), and inhaled corticosteroid (ICS);
resulted in lower rate of moderate or severe exacerbations of COPD, better lung
function, and better health related quality of life than dual therapy or
monotherapy in patients with advanced COPD.
Browse 26 Market Data Tables and
24 Figures spread through 126 Pages and in-depth TOC on ‘Ciclesonide Market, by
Indication (Asthma and Allergic Rhinitis), by Dosage Form (Aerosol and Nasal
Spray), and by Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa) - Global Forecast to 2026’
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2291
Launches and approvals of new
ciclesonide products in key regions is expected to create a conducive
environment for growth of the ciclesonide market over the forecast period. For
instance, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and
Drug Administration approval for its Zetonna (ciclesonide) nasal aerosol for
the treatment of allergic rhinitis and launched it in the U.S. market. In 2012,
Nycomed, a subsidiary of Takeda Pharmaceutical Company Ltd., launched Omnaris
(ciclesonide) nasal spray, indicated for the treatment of adults and
adolescents over the age of 12 with allergic rhinitis in the United Arab
Emirates (UAE). Key players in the market are involved in strategic mergers and
acquisition strategies to enter the lucrative market of ciclesonide and to
widen its portfolio with various ciclesonide products. Such strategic mergers
and acquisitions are expected to support growth of ciclesonide market over the
forecast period. For instance, in 2015, a U.K. based AstraZeneca Plc. acquired
Takeda Pharmaceutical Company Ltd.’s lung business and widen its offerings with
Alvesco, Omnaris ciclesonide. In 2017, Sunovion Pharmaceuticals Inc. (Sunovion)
divested its U.S. market rights of Sunovion’s ciclesonide products: ALVESCO
(ciclesonide) Inhalation Aerosol, OMNARIS (ciclesonide) Nasal Spray, and
ZETONNA (ciclesonide) Nasal Aerosol to Covis Pharma B.V. (Covis Pharma).
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/ciclesonide-market-2291
Key Takeaways of the Ciclesonide
Market:
The global ciclesonide market is
expected to exhibit a CAGR of 9% over the forecast period, owing to increasing
engagement of key players to gain higher market share by employing organic and
in-organic strategies such as new product launch and acquisition and divestment.
Among indication, allergic
rhinitis segment accounted for major market share in 2017. According to the
data published by Allergy UK, allergic rhinitis is a very common non-infectious
rhinitis and in the U.K. it affects 10% and 30% of all adults and as many as
40% of children in 2013. As per the same source, around 57% of adult patients
and up to 88% of children with allergy rhinitis have sleep problems, including
micro-arousals. Such high prevalence of allergic rhinitis is expected to
drastically increase demand for ciclesonide, which is widely used in the
treatment of allergy rhinitis.
Among dosage form, aerosol
segment accounted for highest revenue in 2017, in the market, owing to easy and
direct inhalation of ciclesonide through aerosol, allowing to deliver
appropriate quantity medication to the patient. Furthermore, aerosol therapies present
in the market are widely used for treatment of breathing conditions, including
asthma in adult and adolescent patients aged 12 years and above and symptoms
associated with perennial allergic rhinitis (PAR) and seasonal allergic
rhinitis (SAR) in adults and adolescents 12 years of age and older.
Some of the major players
operating in the global ciclesonide market include AstraZeneca Plc, Cipla
Limited, Sun Pharmaceutical Industries Ltd., and Apotex Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2291
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment